MONT-SAINT-HILAIRE, QUEBEC--(Marketwire - October 01, 2007) - Axcan Pharma Inc. (“Axcan” or the “Company”)-(TSX: AXP)(NASDAQ: AXCA) today announced it has entered into an exclusive license and development agreement with Cellerix SL (“Cellerix”) of Spain, for the North American (United States, Canada and Mexico) rights to Cx401, an innovative biological product in development for the treatment of perianal fistulas. Cx401 uses non-embryonic stem-cells to treat perianal fistulas in Crohn’s and non-Crohn’s Disease patients. A Phase II clinical trial has demonstrated the efficacy and confirmed the safety of Cx401 in the treatment of perianal fistulas. Patent applications have been submitted, which, if granted, could provide protection until 2025.
